Phase 3 Brain Cancer Trial, Recruiting (NCT06419946)

Phase 3 Brain Cancer Trial, Recruiting NCT06419946 Sponsor: Vastra Gotaland Region Condition: Brain Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06419946 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Brain Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been newly diagnosed with a type of brain cancer called glioblastoma or gliosarcoma, with a specific genetic profile called "IDH wild type"
People whose tumor has a particular genetic marker called a "methylated MGMT promoter," which is determined through testing
People who are generally able to carry out daily activities, ranging from fully active to capable of self-care but unable to work (confirm with trial site for exact fitness level required)
People aged between 18 and 70 years old

Who may not be able to join:

People who have had another type of cancer diagnosed within the past 3 years, or who have had a cancer that was not fully cured
People who have previously received chemotherapy or radiation treatment to the head
People who have already started receiving treatments for this tumor that are outside of what the trial requires
People who have serious other health conditions alongside their cancer diagnosis

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Annika Malmström, MD, PhD, University Hospital, Linkoeping

Phone: +46313429741

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06419946

Sponsor: Vastra Gotaland Region

Phase: Phase 3

Status: Recruiting

Condition: Brain Cancer

Trial contact: +46313429741

More information: https://clinicaltrials.gov/study/NCT06419946

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been newly diagnosed with a type of brain cancer called glioblastoma or gliosarcoma, with a specific genetic profile called "IDH wild type"
People whose tumor has a particular genetic marker called a "methylated MGMT promoter," which is determined through testing
People who are generally able to carry out daily activities, ranging from fully active to capable of self-care but unable to work (confirm with trial site for exact fitness level required)
People aged between 18 and 70 years old

Who may not be able to join:

People who have had another type of cancer diagnosed within the past 3 years, or who have had a cancer that was not fully cured
People who have previously received chemotherapy or radiation treatment to the head
People who have already started receiving treatments for this tumor that are outside of what the trial requires
People who have serious other health conditions alongside their cancer diagnosis

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Vastra Gotaland Region

Registry

ClinicalTrials.gov

Start date

1 February 2025

Est. completion

15 December 2031

Where this trial is recruiting

🇦🇹 Austria 🇩🇰 Denmark 🇳🇴 Norway 🇸🇪 Sweden

Primary endpoints

overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov